Under construction – not a live service
Sign in

2025-522551-25-00RecruitingPhase 1

A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus

Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Jul 2026

Next steps

Status (registry)
Recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
35 (estimated)
First submitted
1 Oct 2025
Start date
1 Jul 2026
Lead sponsor
AstraZeneca AB
EU CT number
2025-522551-25-00

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 35
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes. It studies how the drug AZD6793 affects metformin in the body.

Age
18 years and older
Sex
All sexes can join
Disease stage
Type 2 diabetes mellitus

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
PROFIL Institut fuer Stoffwechselforschung GmbHNeussGermanyRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.